We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

January 19, 2019

ResMed-Propeller Deal: What You Need to Know

Commentary
Chandana Fitzgerald
&
2018 was quite the year for M&A activity in healthcare. Some big announcements made waves such as the Amazon-PillPack, Roche-Flatiron, Cigna-Express Scripts, CVS-Aetna, ResMed-Propeller deals, but there were hundreds of smaller ones too. There were 342 acquisitions in 2018 in healthcare, and 4 already in just under 2 weeks of Jan 2019!

List of organisations acquired in 2019 so far. Source: HealthXL platform

We also identified who the top acquirers in 2018 and 2019 (so far) were by number of acquisitions. ResMed acquired 4 during the same period - HEALTHCAREfirst, MatrixCare,  Apacheta via ResMed-owned Brightree, and Propeller Health.

Top Acquirers 2018- 2019, representative list. Source: HealthXL platform

We decided to dig a little bit into a recent one - ResMed’s acquisition of Wisconsin-based Propeller Health for $225 million. Here’s the lowdown on why and what.

First, a sneak peek into ResMed’s very active acquisition decade. Below, you can see their acquisition activity by year (since 2010) and which companies and geographies they’ve invested in since then.

ResMed’s acquisition history (2010- 2018)

Acquisition numbers by year. Source: HealthXL Platform
Companies acquired by ResMed (2010- 2018). Source: HealthXL Platform
Sample of regional spread of acquisition activity by ResMed (2010-2018)

It is quite clear from the above charts that ResMed has definitely been an active investor over the last decade. Their suite of acquisitions have predominantly spanned across SaaS, med device (pulmonary) and digital health.

Why COPD and Asthma?

According to the WHO, asthma affects 334 million people worldwide and COPD 380 million people. According to a report by Research and Markets, the global Asthma and COPD market was valued at US$ 39,021.2 Mn in 2016, and is expected to reach US$ 56,507.7 Mn by 2025, expanding at a CAGR of 4.2% from 2017 to 2025. The lifetime value of Asthma and COPD patients is also very high. For eg, in the USA, the lifetime value of a COPD patient is estimated at US$ 200,000, and the average lifetime value of an asthma patient can be three times as large due to higher life expectancy. So, bottomline is that there is a big opportunity in this market for ResMed (or anybody!)



Investments in COPD & Asthma 2000- 2019. Source: HealthXL platform

ResMed’s COPD Journey So Far

COPD causes the progressive deterioration of respiratory function and often leads to intermittent severe exacerbations as the disease advances. Patient outcomes following hypercapnic exacerbations requiring hospitalisation and acute non-invasive ventilation (NIV) are poor, and few treatment options exist for these patients. Exacerbations and hospitalisations also place a significant burden on healthcare systems. ResMed funded a multi-centre, open label, parallel-group, randomised controlled HOT-HMV1 trial that investigated the effect of home NIV plus oxygen on time to readmission or death in patients with persistent hypercapnia after an acute COPD exacerbation (AECOPD) requiring acute NIV. It aimed to identify whether this treatment strategy could improve outcomes for this patient group. They demonstrated that combining home non-invasive ventilation with home oxygen therapy reduces risks of mortality and hospital readmission and even has the potential to be cost effective for COPD patients.

HERE is the study that was published in JAMA outlining the above results.

Why Propeller Health?

If you have been in hibernation for the last few years, just a quick education on who Propeller Health are: Propeller Health is a digital therapeutics company. Propeller’s digital medicine platform helps patients manage diseases like asthma and COPD by delivering concrete insights on symptoms, triggers and medication use. Patients connect a small sensor to their inhalers, which is paired with a mobile app. Through the Propeller platform, patients receive reminders to take their medication, forecasts on asthma conditions and tips for reducing symptoms. Propeller can reveal a patient’s most common environmental triggers, helping them avoid flare-ups. With the patient’s consent, the platform can communicate to the patient’s physician to show how the patient is doing between appointments.

Propeller has demonstrated clinical outcomes in 18 peer-reviewed studies. They have demonstrated the impact of a digital health intervention on asthma resource utilization, high patient satisfaction with their digital medicines for asthma and effectiveness of population health management using Propeller. Propeller has been shown to significantly decrease SABA use, increase SABA-free days, and improve Asthma Control Test scores, as well as drive 58% increase in medication adherence, a 79% reduction in rescue inhaler use, and a 63% increase in asthma control in their patient population.

Propeller Health has received nine FDA clearances to market their platform for use with inhaled medications, including GlaxoSmithKline’s Ellipta inhaler and Diskus dry powder inhaler and Boehringer’s Respimat Inhaler, to list a few. They also have the European CE mark of approval. The regulatory milestone has proven to be a challenge for a number of digital therapeutics companies, but Propeller Health is ahead of the game.  

Propeller Health has carved out strategic relationships with big pharma companies like GSK, Boehringer Ingelheim, Aptar and Novartis, but their partnerships are not limited to pharma. AIR Louisville is a cross-sector partnership in Louisville, KY that collected data from asthmatics in a real-world setting, in collaboration with 25 public, private and philanthropic organizations to use digital health technology to improve asthma. They found a 78% reduction in rescue inhaler use and a 48% increase in symptom-free days based on crowdsourced real-world data points on inhaler use, combined with environmental data. This study informed municipal policy recommendations, including enhancing tree canopy, tree removal mitigation, zoning for air pollution emission buffers, recommended truck routes, and development of a community asthma notification system.

They have also partnered with Express Scripts to accelerate their distribution.

Propeller is able to support people in the different stages of COPD severity levels and this is complementary to ResMed’s own suite of cloud-connected ventilators for those with stage III and IV COPD, including Astral, Stellar and AirCurve 10 ST-A with iVAPS, as well as ResMed’s new portable oxygen concentrator Mobi.


ResMed Speaks

“We’re excited to welcome Propeller, a fellow digital health innovator and high-performing company, into the ResMed family,” said ResMed CEO Mick Farrell. “Propeller’s digital solutions and partnerships strengthen ResMed’s larger suite of products that can treat millions of people at various stages of their COPD and other chronic diseases, all aimed at improving people’s quality of life, while reducing the effects of these diseases, hospitalizations, and the overall cost of healthcare.”
“ResMed shares our belief that connected health solutions create vastly better experiences and outcomes for people with chronic respiratory disease,” said David Van Sickle, co-founder and CEO of Propeller. “Joining forces enables us to accelerate the adoption of Propeller’s solutions at a global scale, and serve as a powerful platform for a broad set of pharmaceutical and healthcare partners.”

What All This Means

Do you have an opinion on the current oh so active investment and acquisition environment in healthcare? We'd like to hear from you! 

Contact chandana@healthxl.com

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx last mile delivery - HCPs and patients adoption

2nd November @ 11:45AM EDT

Join us in this informal conversation where we will discuss the main challenges around HCP and Patient adoption of DTx. Apply now to connect with peers and learn from fellow thought leaders in this space.

Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Tech Giants, Start-ups or Incumbents, who will disrupt healthcare?

4th November @ 11:30AM EDT

Join our Digital Health Meeting as discuss How do we define disruption in the healthcare industry? What is the ‘extinction event’ healthcare needs and why has it not happened yet? And what are the learnings from Tech Giants’ moves in healthcareApply now to join the conversation and share your thoughts on the topic.

Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software
Featuring
Amanda Goltz
Amanda Goltz
Principal, Business Development, Alexa Health & Wellness at Amazon
Conor Hayes
Conor Hayes
Healthcare Lead, Techvie Software

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Best routes to market for DTx in the EU

18th October @ 10:45AM EDT

Join us as we discuss the best routes to market for DTx in the EU. These 75 minute sessions are guaranteed to be filled with interesting debate and valuable insights, apply now to secure your place.

Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Featuring
Giuseppe Recchia
Giuseppe Recchia
Co-Founder & CEO, daVinci Digital Therapeutics
Nemanja Kovačev
Nemanja Kovačev
Digital Health Lead, Syrmia
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Companion DTx: clinical & economic evidence

20th October @ 10:45AM EDT

Join our Digital Health Meeting focused on Companion DTx: clinical and economic evidence. This informal conversation brings a variety of stakeholders together to discuss and share their thoughts and experiences around this topic.

Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
Featuring
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Céline Ulmann
Céline Ulmann
Head of R&D Digital, Almirall
AI in Healthcare
AI in Healthcare
AI in Healthcare
AI in Healthcare

Masterclass: AI-based diagnostics - learnings from a real-world use case

21st October @ 9:00AM GMT

In this masterclass, Zachary Tan (Advisor at CancerAid; Venture Creation Partner at Aegis Ventures; more info here) & Lisa Zhu (Research Fellow of the Center for Eye Research Australia) will walk us through the key learnings from their latest article in Scientific Reports (Nature) on real-world AI-based screening for diabetic retinopathy in Australia. This early-stage study is one of the first globally to describe the real-world implementation of AI in healthcare.

Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Featuring
Zachary Tan
Zachary Tan
Venture Creation Partner, Aegis Ventures
Lisa Zhu
Lisa Zhu
Research Fellow, CERA
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology
Digital Mental Health & Neurology

Digital Health in Mental Health: Commercialization Models

21st October @ 10:45AM EDT

Join us in this informal conversation where we will discuss the best commercialisation models for digital companies in the mental health space. Our 75 minute sessions are guaranteed to be filled with interesting debate and great conversation.

Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices
Featuring
Robert Garber
Robert Garber
Partner, 7Wire Ventures
Sarah Fisher
Sarah Fisher
Senior Director, Global Markets, External Innovation, Johnson & Johnson Medical Devices

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.